AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity.

AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity.

AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity.

AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity.

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.

AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.

AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM.

AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM.

AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM.

AZD1480 is a novel potent small JAK2 inhibitor with an IC50 of 0.26 nM.

AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.

AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.

AZD1981, as a potent antagonist in a disease relevant cell system, inhibits DK-PGD2-induced CD11b expression in human eosinophils with IC50 of 10 nM.

AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.

AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.

AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.

AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor.

AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.

AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.

AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.

AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.

AZD-3463 is a ALK/IGF1R inhibitor.

AZD-3463 is a ALK/IGF1R inhibitor.

AZD-3463 is a ALK/IGF1R inhibitor.

AZD-3463 is a ALK/IGF1R inhibitor.

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity.

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity.

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity.

AZD-3514 is a potent androgen receptor downregulator with potential anticancer cancer activity.

AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR). It binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR.

AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR). It binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR.

AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR). It binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR.

AZD3839 is a potent and selective inhibitor of human BACE1 with Ki of 26.1 nM.

AZD3839 is a potent and selective inhibitor of human BACE1 with Ki of 26.1 nM.

AZD3839 is a potent and selective inhibitor of human BACE1 with Ki of 26.1 nM.

AZD3839 is a potent and selective inhibitor of human BACE1 with Ki of 26.1 nM.

AZD4017 is a potent, selective, and orally bioavailable11b-HSD1 inhibitor (11b-hydroxysteroid dehydrogenase type 1 inhibitor).

AZD4017 is a potent, selective, and orally bioavailable11b-HSD1 inhibitor (11b-hydroxysteroid dehydrogenase type 1 inhibitor).